Pharmacyte Biotech Inc (OTCMKTS:PMCB) Gets Corrected

[[tagnumber 0]][[tagnumber 1]]After a long slide we finally saw Pharmacyte Biotech Inc (OTCMKTS:PMCB) climb the charts as September came to an end. The ticker managed to recover and go back above the 10 cent per share mark, but it is still uncertain if it can remain there.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Still, [[tagnumber 6]]PMCB[[tagnumber 7]] looks like your regular OTC biotech. The company is yet to produce and market a revenue generating product, but the numbers in its financial reports don’t look that frightening. Here is a quick example of the contents of their 10–Q for the second quarter of the year.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 11]] [[tagnumber 12]]cash: $2.91 million[[tagnumber 13]] [[tagnumber 12]]current assets: $3.01 million[[tagnumber 13]] [[tagnumber 12]]current liabilities: $1.18 million[[tagnumber 13]] [[tagnumber 12]]revenues: ZERO[[tagnumber 13]] [[tagnumber 12]]loss from operations: $1 million[[tagnumber 13]] [[tagnumber 22]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Meanwhile, however, [[tagnumber 6]]PMCB[[tagnumber 7]] is one of the most heavily promoted tickers on the OTC marketplace. We have seen well over 160 promotional emails in this year so far, which is not always a good sign, especially when the company itself has been involved with some of the promotions.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]The management has also been busy issuing regular press releases. After the latest email came in our inbox on October 26 we saw [[tagnumber 6]]PMCB[[tagnumber 7]] climb the charts, aided by PR. Unfortunately, last week didn’t end that well and the ticker fell 3.59% in the last session of the week, closing at $0.10837 per share.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Considering all this you should be sure to do your due diligence and weigh out all the risks before putting any money on the line.[[tagnumber 2]]